/cloudfront-us-east-2.images.arcpublishing.com/reuters/RWP623IKKJP7TETAXRWLNIOO5M.jpg)
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Algeria
|
3.6 million
|
December 24
|
J&J
|
44 million
|
6.0 million
|
|
Angola
|
801,000
|
December 25
|
Pfizer/BioNTech
|
33 million
|
14.8 million
|
|
Benin
|
336,000
|
November 4
|
J&J
|
12 million
|
1.1 million
|
|
Botswana
|
300,000
|
October 1
|
AstraZeneca/Oxford
|
2.5 million
|
560,460
|
|
Burkina Faso
|
504,000
|
December 22
|
J&J
|
21 million
|
1.1 million
|
|
Cameroon
|
336,000
|
November 5
|
J&J
|
27 million
|
1.0 million
|
|
Cape Verde
|
200,000
|
December 7
|
Pfizer/BioNTech
|
556,000
|
324,000
|
|
Central African Republic
|
168,300
|
November 19
|
J&J
|
4.8 million
|
806,700
|
|
Chad
|
117,000
|
October 5
|
Pfizer/BioNTech
|
16 million
|
217,620
|
|
Comoros Islands
|
12,000
|
April 12
|
AstraZeneca/Oxford
|
870,000
|
12,000
|
|
Congo
|
168,000
|
November 15
|
J&J
|
5.5 million
|
470,400
|
|
Democratic Republic of Congo
|
349,830
|
October 21
|
Pfizer/BioNTech
|
90 million
|
2.6 million
|
|
Djibouti
|
151,200
|
July 17
|
J&J
|
988,000
|
175,200
|
|
Egypt
|
2.2 million
|
February 20
|
Pfizer/BioNTech
|
102 million
|
29.0 million
|
|
Eswatini
|
100,620
|
October 6
|
Pfizer/BioNTech
|
1.1 million
|
429,420
|
|
Ethiopia
|
13.1 million
|
February 2
|
J&J
|
115 million
|
27.5 million
|
|
Gabon
|
101,790
|
November 1
|
Pfizer/BioNTech
|
2.2 million
|
370,410
|
|
Gambia
|
100,620
|
March 3
|
Pfizer/BioNTech
|
2.4 million
|
477,420
|
|
Ghana
|
1.7 million
|
December 24
|
Pfizer/BioNTech
|
31 million
|
16.3 million
|
|
Guinea
|
168,000
|
November 14
|
J&J
|
13 million
|
1.7 million
|
|
Guinea-Bissau
|
28,800
|
August 18
|
AstraZeneca/Oxford
|
2.0 million
|
360,000
|
|
Iran
|
700,000
|
January 14
|
AstraZeneca/Oxford
|
84 million
|
5.7 million
|
|
Iraq
|
500,000
|
August 14
|
Pfizer/BioNTech
|
40 million
|
836,000
|
|
Ivory Coast
|
816,660
|
January 3
|
Pfizer/BioNTech
|
26 million
|
8.6 million
|
|
Jordan
|
146,400
|
June 3
|
AstraZeneca/Oxford
|
10 million
|
436,800
|
|
Kenya
|
1.9 million
|
February 28
|
Pfizer/BioNTech
|
54 million
|
18.6 million
|
|
Lebanon
|
613,340
|
December 22
|
N/A
|
6.8 million
|
982,940
|
|
Lesotho
|
169,070
|
November 19
|
J&J
|
2.1 million
|
644,090
|
|
Liberia
|
168,000
|
November 27
|
J&J
|
5.1 million
|
830,400
|
|
Libya
|
1.2 million
|
December 20
|
Pfizer/BioNTech
|
6.9 million
|
1.9 million
|
|
Madagascar
|
240,000
|
February 17
|
J&J
|
28 million
|
1.9 million
|
|
Malawi
|
277,080
|
February 26
|
AstraZeneca/Oxford
|
19 million
|
2.0 million
|
|
Mali
|
50,400
|
January 7
|
AstraZeneca/Oxford
|
20 million
|
1.7 million
|
|
Mauritania
|
201,600
|
February 7
|
AstraZeneca/Oxford
|
4.6 million
|
2.2 million
|
|
Mauritius
|
203,580
|
January 12
|
Pfizer/BioNTech
|
1.3 million
|
387,270
|
|
Morocco
|
1.5 million
|
January 29
|
Pfizer/BioNTech
|
37 million
|
2.7 million
|
|
Mozambique
|
1.2 million
|
February 11
|
AstraZeneca/Oxford
|
31 million
|
8.4 million
|
|
Namibia
|
19,890
|
February 18
|
Pfizer/BioNTech
|
2.5 million
|
512,690
|
|
Niger
|
398,000
|
February 4
|
Pfizer/BioNTech
|
24 million
|
1.6 million
|
|
Nigeria
|
2.0 million
|
February 7
|
J&J
|
206 million
|
17.2 million
|
|
Palestinian Territories
|
203,580
|
January 31
|
Pfizer/BioNTech
|
4.7 million
|
1.3 million
|
|
Rwanda
|
1.1 million
|
January 15
|
N/A
|
13 million
|
3.9 million
|
|
Sao Tome and Principe
|
24,000
|
March 3
|
AstraZeneca/Oxford
|
219,000
|
24,000
|
|
Senegal
|
302,400
|
February 10
|
J&J
|
17 million
|
3.2 million
|
|
Seychelles
|
39,780
|
December 17
|
Pfizer/BioNTech
|
98,460
|
74,880
|
|
Sierra Leone
|
168,000
|
November 23
|
J&J
|
8.0 million
|
785,310
|
|
Somalia
|
250,380
|
March 3
|
Pfizer/BioNTech
|
16 million
|
1.4 million
|
|
South Africa
|
5.6 million
|
July 31
|
Pfizer/BioNTech
|
59 million
|
5.6 million
|
|
South Sudan
|
336,000
|
December 21
|
J&J
|
11 million
|
908,450
|
|
Sudan
|
604,800
|
February 16
|
J&J
|
44 million
|
3.9 million
|
|
Syria
|
4.0 million
|
January 26
|
J&J
|
17 million
|
5.7 million
|
|
Tanzania
|
1.6 million
|
January 19
|
Pfizer/BioNTech
|
60 million
|
4.7 million
|
|
Togo
|
633,600
|
November 25
|
J&J
|
8.3 million
|
3.0 million
|
|
Tunisia
|
310,050
|
January 28
|
Pfizer/BioNTech
|
12 million
|
4.4 million
|
|
Uganda
|
433,300
|
February 16
|
Moderna
|
46 million
|
11.7 million
|
|
Yemen
|
100,800
|
February 24
|
AstraZeneca/Oxford
|
30 million
|
2.2 million
|
|
Zambia
|
907,200
|
January 28
|
N/A
|
18 million
|
4.0 million
|
|
Zimbabwe
|
2.6 million
|
January 19
|
N/A
|
15 million
|
3.5 million
|
User login
Language
Anonymous's groups in this site
User is not a member of any group.
Your groups across all your sites
User is not a member of any group.
Recent Content
Who's online
There are currently 0 users online.
You are here
Vaccines delivered under COVAX sharing scheme for poorer countries --data
Primary tabs
Vaccines delivered under COVAX sharing scheme for poorer countries --data
Fri, 2022-03-04 11:12 — mike kraftMarch 4 (Reuters) - The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delivered 1.34 billion COVID-19 vaccine doses to 144 countries, GAVI data shows.
In December COVAX set a target of achieving 70% COVID-19 immunization coverage by mid-2022.
The following tables list countries that have received vaccines under the scheme, sorted alphabetically:
AFRICA & MIDDLE EAST
EUROPE
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Albania
|
40,800
|
June 2
|
AstraZeneca/Oxford
|
2.8 million
|
120,000
|
|
Armenia
|
187,200
|
September 5
|
AstraZeneca/Oxford
|
3.0 million
|
261,200
|
|
Azerbaijan
|
84,000
|
April 4
|
AstraZeneca/Oxford
|
10 million
|
84,000
|
|
Bosnia
|
32,760
|
May 10
|
Pfizer/BioNTech
|
3.3 million
|
82,560
|
|
Georgia
|
43,200
|
March 13
|
AstraZeneca/Oxford
|
3.7 million
|
43,200
|
|
Kosovo
|
515,970
|
February 10
|
Pfizer/BioNTech
|
1.8 million
|
1.2 million
|
|
Moldova
|
100,620
|
January 27
|
Pfizer/BioNTech
|
2.6 million
|
744,620
|
|
Montenegro
|
24,000
|
March 28
|
AstraZeneca/Oxford
|
622,000
|
24,000
|
|
North Macedonia
|
250,380
|
February 7
|
Pfizer/BioNTech
|
2.1 million
|
312,780
|
|
Serbia
|
115,200
|
August 25
|
AstraZeneca/Oxford
|
6.9 million
|
292,800
|
|
Ukraine
|
1.0 million
|
January 19
|
Pfizer/BioNTech
|
44 million
|
8.8 million
|
ASIA & PACIFIC
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Afghanistan
|
2.0 million
|
February 2
|
J&J
|
39 million
|
9.0 million
|
|
Bangladesh
|
342,400
|
February 2
|
Pfizer/BioNTech
|
165 million
|
34.8 million
|
|
Brunei
|
24,000
|
April 2
|
AstraZeneca/Oxford
|
437,000
|
24,000
|
|
Cambodia
|
300,000
|
December 19
|
AstraZeneca/Oxford
|
17 million
|
2.9 million
|
|
East Timor
|
100,620
|
February 12
|
Pfizer/BioNTech
|
1.3 million
|
494,040
|
|
Fiji
|
50,400
|
November 18
|
Moderna
|
896,000
|
302,480
|
|
Indonesia
|
2.6 million
|
January 28
|
AstraZeneca/Oxford
|
274 million
|
48.8 million
|
|
Kiribati
|
56,000
|
August 21
|
AstraZeneca/Oxford
|
119,000
|
104,000
|
|
Kyrgyzstan
|
149,760
|
February 1
|
Pfizer/BioNTech
|
6.6 million
|
800,300
|
|
Laos
|
1.7 million
|
January 26
|
Pfizer/BioNTech
|
7.3 million
|
7.6 million
|
|
Malaysia
|
559,200
|
September 17
|
AstraZeneca/Oxford
|
32 million
|
1.4 million
|
|
Maldives
|
210,600
|
January 28
|
Pfizer/BioNTech
|
541,000
|
664,540
|
|
Mongolia
|
899,730
|
October 6
|
Pfizer/BioNTech
|
3.3 million
|
1.3 million
|
|
Nauru
|
7,200
|
April 2
|
AstraZeneca/Oxford
|
10,830
|
7,200
|
|
Nepal
|
800,000
|
February 7
|
AstraZeneca/Oxford
|
29 million
|
14.2 million
|
|
Pakistan
|
1.5 million
|
December 28
|
Moderna
|
221 million
|
39.1 million
|
|
Papua New Guinea
|
302,400
|
August 6
|
J&J
|
8.9 million
|
580,400
|
|
Philippines
|
769,860
|
March 3
|
Pfizer/BioNTech
|
110 million
|
52.6 million
|
|
Samoa
|
112,000
|
August 23
|
AstraZeneca/Oxford
|
198,410
|
136,000
|
|
Solomon Islands
|
100,620
|
November 16
|
Pfizer/BioNTech
|
687,000
|
209,420
|
|
Sri Lanka
|
820,000
|
December 20
|
Pfizer/BioNTech
|
22 million
|
5.0 million
|
|
Tajikistan
|
501,200
|
February 21
|
AstraZeneca/Oxford
|
9.5 million
|
5.4 million
|
|
Tonga
|
7,000
|
February 15
|
N/A
|
106,000
|
67,800
|
|
Tuvalu
|
4,800
|
April 8
|
AstraZeneca/Oxford
|
11,800
|
4,800
|
|
Uzbekistan
|
2.8 million
|
February 17
|
Moderna
|
34 million
|
12.7 million
|
|
Vanuatu
|
24,000
|
May 19
|
AstraZeneca/Oxford
|
307,000
|
24,000
|
|
Vietnam
|
6.3 million
|
January 25
|
Pfizer/BioNTech
|
97 million
|
38.7 million
|
AMERICAS
|
COUNTRY
|
LATEST DELIVERY
|
DELIVERY DATE
|
VACCINE TYPE
|
POPULATION
|
TOTAL DELIVERED
|
|---|---|---|---|---|---|
|
Antigua and Barbuda
|
19,200
|
November 22
|
N/A
|
98,000
|
60,000
|
|
Argentina
|
960,400
|
October 12
|
AstraZeneca/Oxford
|
45 million
|
3.9 million
|
|
Bahamas
|
57,330
|
October 18
|
Pfizer/BioNTech
|
393,000
|
124,530
|
|
Barbados
|
14,040
|
December 16
|
Pfizer/BioNTech
|
287,000
|
114,840
|
|
Belize
|
58,500
|
October 26
|
Pfizer/BioNTech
|
398,000
|
159,300
|
|
Bermuda
|
9,600
|
April 6
|
AstraZeneca/Oxford
|
64,000
|
9,600
|
|
Bolivia
|
1.3 million
|
February 16
|
Pfizer/BioNTech
|
12 million
|
8.0 million
|
|
Brazil
|
2.0 million
|
September 20
|
Sinovac
|
213 million
|
11.9 million
|
|
Chile
|
331,000
|
May 20
|
AstraZeneca/Oxford
|
19 million
|
489,400
|
|
Colombia
|
117,000
|
March 1
|
Pfizer/BioNTech
|
51 million
|
16.6 million
|
|
Costa Rica
|
200,070
|
February 28
|
Pfizer/BioNTech
|
5.1 million
|
1.6 million
|
|
Dominica
|
30,240
|
February 4
|
Moderna
|
72,000
|
133,920
|
|
Dominican Republic
|
184,800
|
August 27
|
AstraZeneca/Oxford
|
11 million
|
463,200
|
|
Ecuador
|
1.5 million
|
February 15
|
Pfizer/BioNTech
|
18 million
|
3.8 million
|
|
El Salvador
|
188,370
|
August 27
|
Pfizer/BioNTech
|
6.5 million
|
3.6 million
|
|
Grenada
|
69,030
|
December 16
|
Pfizer/BioNTech
|
113,000
|
114,630
|
|
Guatemala
|
680,940
|
January 27
|
Pfizer/BioNTech
|
17 million
|
5.0 million
|
|
Guyana
|
28,800
|
January 14
|
J&J
|
787,000
|
291,540
|
|
Haiti
|
151,200
|
February 14
|
Moderna
|
11 million
|
1.1 million
|
|
Honduras
|
250,040
|
October 28
|
Moderna
|
9.9 million
|
4.8 million
|
|
Jamaica
|
100,000
|
February 21
|
AstraZeneca/Oxford
|
3.0 million
|
1.7 million
|
|
Mexico
|
4.0 million
|
March 4
|
AstraZeneca/Oxford
|
129 million
|
21.3 million
|
|
Nicaragua
|
993,600
|
January 24
|
J&J
|
6.6 million
|
4.7 million
|
|
Panama
|
74,400
|
September 15
|
AstraZeneca/Oxford
|
4.3 million
|
148,800
|
|
Paraguay
|
466,830
|
January 24
|
Pfizer/BioNTech
|
7.1 million
|
1.7 million
|
|
Peru
|
1.2 million
|
November 10
|
Sinopharm
|
33 million
|
3.6 million
|
|
Saint Kitts and Nevis
|
21,600
|
April 7
|
AstraZeneca/Oxford
|
53,000
|
21,600
|
|
Saint Lucia
|
7,200
|
December 28
|
J&J
|
184,000
|
197,430
|
|
Saint Vincent and the Grenadines
|
70,200
|
December 14
|
Pfizer/BioNTech
|
111,000
|
115,800
|
|
Suriname
|
64,800
|
December 14
|
AstraZeneca/Oxford
|
587,000
|
144,000
|
|
Trinidad and Tobago
|
84,000
|
November 27
|
Sinopharm
|
1.4 million
|
185,200
|
|
Uruguay
|
50,400
|
September 1
|
AstraZeneca/Oxford
|
3.5 million
|
148,800
|
|
Venezuela
|
3.1 million
|
January 17
|
Sinopharm
|
28 million
|
12.1 million
|
Sources: WHO, UNICEF, GAVI, releases from local authorities
###
Country / Region Tags:
General Topic Tags:
Problem, Solution, SitRep, or ?:
Groups this Group Post belongs to:
Recent Comments